MGC Pharmaceuticals Ltd
ASX:MXC
MGC Pharmaceuticals Ltd
ASX:MXC
Price:
0.415
AUD
Market Closed
Market Cap:
AU$18.2m
Relative Value
There is not enough data to reliably calculate the relative value of MXC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MXC
Relative Value
Base Case
Not Available
Multiples Across Competitors
MXC Competitors Multiples
MGC Pharmaceuticals Ltd Competitors
MGC Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
MGC Pharmaceuticals Ltd
ASX:MXC
|
18.2m AUD | 13.7 | -1.1 | -0.8 | -0.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
963B USD | 14.8 | 46.6 | 31.4 | 33.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
599.3B USD | 6.4 | 22.3 | 15.5 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282.3B CHF | 4.6 | 30.1 | 12.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
244.3B CHF | 5.6 | 22.6 | 13.9 | 17.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233.1B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.9B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
